Zhengbin (Bing) Yao is Chief Executive Officer and President of ArriVent BioPharma, Inc. (AVBP). The company reported total compensation of $9,374,153 for fiscal year 2025.
| Salary | $596,667 |
|---|---|
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $8,405,486 |
| Non-equity incentive plan | $358,000 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $14,000 |
| Total | $9,374,153 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure ArriVent BioPharma, Inc. filed April 28, 2026, accession 0001104659-26-050337.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | Chief Executive Officer and President | $596,667 | $0 | $0 | $8,405,486 | $358,000 | $0 | $14,000 | $9,374,153 |
| FY2024 | Chief Executive Officer and President | $558,183 | $0 | $0 | $1,596,043 | $238,623 | $0 | $13,800 | $2,406,649 |
Totals as disclosed in each year's own compensation disclosure for ArriVent BioPharma, Inc..
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Zhengbin (Bing) Yao this page | Chief Executive Officer and President | $9,374,153 |
| Stuart Lutzker | President, Research and Development | $3,431,717 |
| Winston Kung | Chief Financial Officer and Treasurer | $3,407,068 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full ArriVent BioPharma, Inc. compensation brief.
Zhengbin (Bing) Yao's compensation sits inside ArriVent BioPharma, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.